TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00702546

Intervention type: DRUG
Intervention: corifollitropin alfa
Description: Single injection of 100 μg corifollitropin alfa administered under protocol P05690

Intervention type: BIOLOGICAL
Intervention: recFSH (follitropin alfa)
Description: Daily recFSH administered under protocol P05690

Intervention type: DRUG
Intervention: gonadatropin releasing hormone (GnRH) antagonist ganirelix
Description: GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690

Intervention type: DRUG
Intervention: gonadatropin releasing hormone (GnRH) antagonist ganirelix
Description: GnRH antagonist ganirelix administered SC at a dose of 0.25 mg/day under protocol P05690

Intervention type: DRUG
Intervention: human chorion gonadatropin (hCG)
Description: hCG 5,000 IU or 10,000 IU administered SC under protocol P05690

Intervention type: DRUG
Intervention: human chorion gonadatropin (hCG)
Description: hCG 5,000 IU or 10,000 IU administered SC under protocol P05690

Intervention type: BIOLOGICAL
Intervention: progesterone
Description: Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.

Intervention type: BIOLOGICAL
Intervention: progesterone
Description: Under protocol P05690, progesterone was started on the day of oocyte pick-up (OPU) and continued for at least 6 weeks or up to menses. Participants received at least 600 mg/day vaginally or 50 mg/day IM.

Intervention type: DRUG
Intervention: placebo-recFSH (follitropin alfa)
Description: Placebo-recFSH at the equivalent volume of 150 IU/day administered under protocol P05690

Intervention type: DRUG
Intervention: placebo-corifollitropin alfa
Description: Single SC injection of placebo-corifollitropin alfa on Day 2 or 3 of the menstrual cycle, administered under protocol P05690

Intervention type: BIOLOGICAL
Intervention: open-label recFSH
Description: Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590

Intervention type: BIOLOGICAL
Intervention: open-label recFSH
Description: Open-label recFSH up to a maximum dose of 200 IU/day, administered under protocol P0590
Study: NCT03592823

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydroxychloroquine Sulfate 200 Mg Tablet
Description: 200 mg, bidpo.
Study: NCT04817930

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Polyetheretherketone patient specific implant
Description: a customized peek patient specific implant is place to augment the chin

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Computer guided advancement genioplasty
Description: advancement genioplasty using patient specific cutting and positioning surgical stents
Study: NCT02220777

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8477
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8477
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP8477
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: omeprazole
Description: oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: oral
Study: NCT04525456

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Reduxium
Description: Single-centre, one-arm, prospective study of 20 healthy subjects who will be given Reduxium supplementation for 14 days.
Study: NCT01695447

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: duct-to-mucosa

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: invagination

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Internal stent
Description: Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Internal stent
Description: Internal stent may be used during pancreaticojejunostomy according to the situation of pancreatic duct and experience of the surgeon.
Study: NCT00927550

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: lithium
Description: Patients allocated to lithium will be administered an oral starting dose ranging between 150 and 300 milligrams. Suggested final oral dose will have to achieve plasma levels of 0.4 to 1.0 mmol/L. Clinicians will be free of increasing or decreasing the dose according to clinical status and circumstances. Dose changes will be recorded. Following randomization, treatment is to be taken daily for 1 year unless some clear reason to stop develops. Patients allocated to the lithium arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Any other pharmacological treatment will be allowed.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: usual care
Description: Patients allocated to the control arm will receive usual pharmacological and non-pharmacological treatment as clinically indicated. Patients allocated to the control arm will not be allowed to receive lithium. Any other pharmacological treatment will be allowed.
Study: NCT04682340

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum BPA
Description: Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum BPA
Description: Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.

Intervention type: DIAGNOSTIC_TEST
Intervention: Serum BPA
Description: Serum BPA levels will be compared between women with autoimmune thyroid disease and normal women.
Study: NCT01536613

Intervention type: DRUG
Intervention: biphasic insulin aspart 30
Description: The insulin dose and regimen were individualised at the physician's discretion. Insulin was administered by subcutaneous injection using an injection device
Study: NCT01956955

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin ,alteplase, unfractionated heparin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: enoxaparin ,alteplase, unfractionated heparin
Study: NCT00644735

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esomeprazole

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lansoprazole
Study: NCT01939821

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational and counselling program
Description: Educational and counselling program: In addition to educational meeting and printed educational material the investigators will include the use of local opinion leaders and educational outreach . Local opinion leaders are defined as use of providers nominated by their colleges as educationally influential. Opinion leadership is the degree to which an individual is able to influence other individual's attitudes or overt behavior informally in a desired way with relative frequency. Educational outreach is defined as use of a trained person who meets with providers in their practice setting to give information with the intent of changing the providers practice.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Educational program
Description: Educational program: Educational meeting and printed educational material Educational meeting is defined as participation of healthcare providers in conference, lectures, workshops or traineeships. The investigators want to organize the educational meetings as an interactive workshop that target knowledge, attitudes, and skills at the individual healthcare professional/peer group level. Printed educational material is defined as distribution of published or printed recommendations for clinical care, including clinical practice guidelines. In general, printed educational material target knowledge and potential skill gaps of individual healthcare professionals.
Study: NCT00361842

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CPX-1 (Irinotecan HCl:Floxuridine) Liposome Injection
Description: CPX-1 Liposome Injection is a liposomal formulation of a fixed combination of the antineoplastic drugs irinotecan HCl and floxuridine.
Study: NCT00949598

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: letrozole
Description: Given orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamoxifen citrate
Description: Given orally
Study: NCT03459612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lasmiditan
Description: Administered orally

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered orally

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Diphenhydramine
Description: Administered orally
Study: NCT04528290

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod capsule formulation of 0.92mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ozanimod
Description: Ozanimod, granule formulation of 0.92mg
Study: NCT03282578

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sternalock 360 sternal plating system
Description: The SternaLock 360 system is a band and plating system designed to improve sternal stability. 3 bands surround the sternum to oppose the bones (like wires), but an additional 3 plate system prevents anterior posterior displacement and provides a rigid fixation.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Sternal Wires
Description: Stainless steel wires are applied in a figure of 8 configuration to close the sternum
Study: NCT02570256

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deficit-fields to reduce error
Description: Stroke survivors exhibit error in both reaching extent and abnormal curvatures of motion. Prior error augmentation techniques multiply error by a constant at each instant during movement. However, magnification of spurious errors may provoke over-compensation. We hypothesize that a deficit-field design, using the statistics of a patient's errors to customize training, will provide optimal augmentation that varies during motion as needed. We will compare the training effects of error deficit-fields with previous methods of error augmentation to improve reaching ability.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deficit-fields to expand range of motion
Description: Motor deficits manifest in the workspace limitations of joints, i.e. reduced range of motion, uneven extension-flexion, inter-joint coupling, and unwanted synergies. Our work builds upon these ideas by augmenting self-directed movement for training coordination. We found that amplifying augmentation can expand motor exploration and improve skill retention in patients. Using motor exploration patterns from each patient, we will form customized deficit-fields to recover normal joint workspace. We will compare augmentation training that either amplifies or diminishes the observed deficits (Expt-1). We also compare deficit-fields with our prior augmentation methods to determine the added value of increased customization (Expt-2).

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Deficit-fields to improve function
Description: Clinicians have recognized the benefits of training on everyday tasks (Hubbard, Parsons et al. 2009), as well as practice with whole-body actions (Boehme 1988; Bohannon 1995). However, typical robotic systems have only a single contact point and cannot drive the multiple joints involved in functional tasks. Visual distortions (e.g. a shift, rotation or stretch) can promote adaptation even without forces. Here we present visual distortion of whole body movement during manual tasks during standing, including reaching, grasping, and object manipulation. We compare the training effects of feedback based on deficit-fields versus practice with normal vision.
Study: NCT00468065

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: VeinViewer
Description: Veinveiwer is used to view veins subQ

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Veinviewer
Description: near infrared light reveals veins subcutaneously
Study: NCT02053740

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Add R-S-Y-R-T (500 mg 3 times per day) for 6 months

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Routine western medicine

Intervention type: DRUG
Group type: OTHER
Intervention: Routine western medicine
Study: NCT00592735

Intervention type: PROCEDURE
Intervention: laparoscopic gastric banding
Description: standard surgical procedure
Study: NCT00496834

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: losartan potassium
Description: Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: carvedilol
Description: Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Comparator: losartan (+) hydrochlorothiazide (HCTZ)
Description: Once daily , Cozaar® (losartan) 50 mg, Cozaar® (losartan) 100 mg, Cozaar Plus®-pro Tab. (losartan 100 mg/ hydrochlorothiazide 12.5 mg) or Cozaar Plus®-F Tab. (losartan 100 mg / hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Comparator: carvedilol (+) hydrochlorothiazide
Description: Once daily, Dilatrend Tab® (carvedilol) 12.5 mg, Dilatrend Tab® (carvedilol) 25 mg, Dilatrend Tab® (carvedilol) 25 mg plus half Dichlozid Tab® (hydrochlorothiazide 25 mg) or Dilatrend Tab® (carvedilol) 25 mg plus full Dichlozid Tab® (hydrochlorothiazide 25 mg), 24 weeks (Patients who have failed in blood pressure control, increase the study medication dose step by step according to the titration plan)
Study: NCT03134261

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: WB-MRI
Description: scanning methods

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: WB-MRI
Description: scanning methods

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: WB-MRI
Description: scanning methods
Study: NCT01777295

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: Placebo
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Intramuscular vaccination in the deltoid region of the non-dominant arm according to protocol schedule.
Study: NCT00600405

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: tamsulosin
Description: Tamsulosin 0.4 mg orally daily for ten days.

Intervention type: DRUG
Group type: OTHER
Intervention: Standard therapy with ibuprofen and oxycodone.
Description: Oxycodone: 5mg, one to two tablets every four to six hours as needed for pain. Ibuprofen: 800 mg, one three times a day with food as needed for pain.
Study: NCT03134261

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: SPECT-CT
Description: scanning methods

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Cholin-PET-CT
Description: scanning methods

Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: PSMA-PET-CT
Study: NCT02900313

Intervention type: OTHER
Group type: OTHER
Intervention: cardiac surgery
Description: Cohort of patients who are more than 18 years having cardiac surgery and having benefited from a dosage of serum phosphorus level and serum creatinine during all the duration of the hospitalisation
Study: NCT03115229

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Protective Nursing Interventions for Reduction Obesity Risk
Description: Applications for the experimental group for 11 weeks are grouped under three headings.~These; Nutritional habits, practices for physical activity, and motivational messages sent via social media.~Nutritional practices: Nutritional practices consist of group trainings, individual practices and collective events.~Practices for physical activity: Group trainings, group exercises, individual exercises and collective activities. Physical activity was done for 3 days per week and 45-60 minutes every seans for 8 weeks. In addition, activities such as collective nature walks and cycling have been carried out Practices through social media: For physical activity and healthy eating; Motivational messages were sent twice a week for 11 weeks.
Study: NCT00778518

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARX201
Description: Reconstituted lyophilized drug product at 2.5 mg/wk; 3 periods over six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARX201
Description: Reconstituted lyophilized drug product at 5.0 mg/wk; 3 periods over six months.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: ARX201
Description: Reconstituted lyophilized drug product at 10.0 mg/wk; 3 periods over six months.
Study: NCT01180790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0141625 (Sovaprevir)
Description: 200 mg oral capsule once daily
Study: NCT02999724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gabapentin
Description: Gabapentin 300-600 mg 1 hour preop

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo capsule(s) 1 hour preop
Study: NCT01733043

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study: NCT02381769

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Soybean based lipid emulsion
Study: NCT04940416

Intervention type: DEVICE
Intervention: Neurofit (oculometric testing)
Description: The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes.

Intervention type: DEVICE
Intervention: Neurofit (oculometric testing)
Description: The Neurofit test involves sitting on a chair with a head and chin rest to maintain stability. Patients will then follow a moving object on the computer screen with their eyes which allows estimation of individual oculometrics along with a composite score. No physical contact or placement of invasive devices will be performed. The total time for completion of all the tests is estimated at 30 minutes.
Study: NCT02018354

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Lateral Extra-Articular Tenodesis (LET)
Description: Lateral extra-articular tenodesis: A 1cm wide x 8cm long strip of iliotibial band is fashioned, leaving the Gerdys tubercle attachment intact. The graft is tunneled under the fibular collateral ligament (FCL) and attached to the femur with a Richards' staple (Smith \& Nephew), just distal to the intermuscular septum, proximal to the femoral insertion of the FCL. Fixation is performed with the knee at 70 degrees flexion, neutral rotation. Minimal tension is applied to the graft. The free end is then looped back onto itself and sutured using the No. 1 vicryl.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ACL Reconstruction
Description: Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: ACL Reconstruction
Description: Anatomic ACL reconstruction using a four-strand autologous hamstring graft. If the diameter of the graft is found to be less than 7.5mm, semitendinosus will be tripled (5 strand graft) providing a greater graft diameter. Femoral tunnels will be drilled using an anteromedial portal technique, with femoral fixation provided by an Endobutton or equivalent. Tibial fixation will be provided by interference screw.
Study: NCT02687906

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vabomere
Description: Vabomere (meropenem-vaborbactam) for IV injection
Study: NCT03005613

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ischial spine fascia fixation
Description: The participants will receive ischial spine fascia fixation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: sacrospinous ligament fixation
Description: The participants will receive sacrospinous ligament fixation.
Study: NCT02795520

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OTS167IV
Study: NCT02624388

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Estrogen-like compound (isoflavone) derived from soybeans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Genistein
Description: Estrogen-like compound (isoflavone) derived from soybeans

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pill that contains no medicine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Pill that contains no medicine
Study: NCT01180790

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0141625 (Sovaprevir)
Description: 200 mg oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0141625 (Sovaprevir)
Description: 400 mg oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0141625 (Sovaprevir)
Description: 400 mg oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0141625 (Sovaprevir)
Description: 800 mg oral capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ACH-0141625 (Sovaprevir)
Description: 800 mg oral capsule once daily

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Powder in capsule once daily

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha-2a
Description: 180 micrograms (ug) once a week by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha-2a
Description: 180 micrograms (ug) once a week by subcutaneous injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pegylated Interferon alpha-2a
Description: 180 micrograms (ug) once a week by subcutaneous injection
Study: NCT01925235

Intervention type: PROCEDURE
Intervention: remote ischemic preconditioning